# US 2017/0285007 A1 · Screening methods for thyroid hormone disruptors based on co-regulator involved simulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285007 A1
- Document ID: US20170285007A1
- Status: Published application
- Kind: A1
- Application number: 15/203,877
- Filed: 2016-07-07
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Nanjing University
- Applicants: Nanjing University
- Inventors: Hongxia Yu; Wei Shi; Qinchang Chen; Xiaoxiang Wang
- Web page: https://patentgrep.com/patent/US20170285007A1

## CPC

- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/30: Detection of binding sites or motifs
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor).The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding free energy, therefore, may be used for screening of thyroid hormone disruptors among environmental pollutants. Upon more comprehensive consideration of the functioning mechanism of thyroid hormone receptor, the present invention is able to sufficiently identify thyroid hormone disruptors as agonists and antagonists, and gives more accurate prediction of the disrupting potency. Further, since nuclear receptors, just as thyroid hormone receptor, are strongly associated with co-regulators, the method may be expanded to the screening of nuclear receptor mediated endocrine disruptors.

## Claims

### Claim 1

A screening method for thyroid hormone disruptors based on co-regulator involved simulations, comprising:
1) apo conformations of thyroid hormone (TH) receptor (TR) ligand binding domain (LBD) are constructed by used of the reported protein crystal as templates, followed by quality evaluation and structural optimization; ligand structures are built and optimized; the ligands are docked into the TRs to form ligand-TR complexes;
Molecular dynamics (MD) simulations are performed for the ligand-TR complexes;
2) equilibrated conformations are extracted from the MD trajectories; the relative ligands are identified as passive antagonists for those helix-12s (H12s)are induced to block the coactivator binding site;
3) coactivator and corepressor are docked to the equilibrated conformations extracted in step 2) whose co-regulator binding sites are not blocked and thus be exposed to co-regulators; whether the equilibrated conformations are more attractive to coactivator or corepressoris estimated according to the docking scores; the relative ligands are identified as agonists if the equilibrated conformations are more selectively bind to coactivators; the relative ligands are identified as activeantagonists if the equilibrated conformations are more selectively bind to corepressors;
4) for those identified as agonists in step 3), MD simulations are performed again for the obtained ligand-TR-coactivator complexes; for those identified as active antagonists in step 3), MD simulations are performed again for the obtained ligand-TR-corepressor complexes;
5) bioassays are performed for the representative TH disrupting chemicals to obtain the relative disrupting potencies;binding free energies with TR are calculated for the passive antagonists, active antagonists and agonists in step 2) and4); the predicted TH disrupting potencies are calculated by the prediction models achieved by regression analysis between binding free energy and relative TH disrupting potencies.

### Claim 2 (depends on 1)

The method of claim 1, wherein the construction of the apo conformations in step 1) is based on homology modeling: the loop between H11 and H12 is constructed according to the template coded 1A52 in the protein database; the rest part is constructed based on the reported crystal structures of TRs in the protein database.

### Claim 3 (depends on 1)

The method of claim 1, wherein the optimization of ligand structures in step 1)is first performedwith MM2 (Molecular Mechanics, Allinger Force Field version 2), followed by Powell gradient algorithm with the Tripos force field.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MD simulations of ligand-TR complexes in step 1) are performed following the protocol: CHARMM force fields are applied to the receptors and ligands, respectively; each complex is immersed with TIP3P water molecules in a box, keeping the minimum distance between the complex and the boundary larger than 1.4 nm; Na+ and Cl− ions are added to neutralize the system; all MD simulations are performed in the NPT (constant pressure and temperature) ensemble in 1 atm, 300 K, with periodic boundary conditions; electrostatic interactions are calculated with the particle mesh Ewald method, with van der Waals interactions cutoff of 1.0 nm; all simulations are performed for 20-22 ns using a 2 fs time step, and snapshots for analysis are saved every 2 ps.

### Claim 5 (depends on 1)

The method of claim 1, wherein the MD simulations of ligand-TR-coactivator/corepressor complexes in step 4) are performed following the protocol: CHARMM force fields are applied to the receptors with coactivator/corepressor and ligands, respectively; each complex is immersed with TIP3P water molecules in a box, keeping the minimum distance between the complex and the boundary larger than 1.4 nm; Na+ and Cl− ions are added to neutralize the system; all MD simulations are performed in the NPT (constant pressure and temperature) ensemble in 1 atm, 300 K, with periodic boundary conditions; electrostatic interactions are calculated with the particle mesh Ewald method, with van der Waals interactions cutoff of 1.0 nm; all simulations are performed for 20-22 ns using a 2 fs time step, and snapshots for analysis are saved every 2 ps.

### Claim 6 (depends on 1)

The method of claim 1, wherein the blocking of coactivator binding site in step 2) is evaluated according to the distance between H12 and key residues: for TRα, H12 is considered blocking coactivator binding site if the distances with V284 and K306 are less than 3 Å, and the distances with K288 and 1302 are less than 5 Å; for TRβ, H12 is considered blocking coactivator binding site if the distances with V230 and K252 are less than 3 Å, and the distances with K234 and 1248 are less than 5 Å.

### Claim 7 (depends on 1)

The method of claim 1, wherein calculation of binding free energy in step 5) is based on MM-PBSA (molecular mechanics Poisson-Boltzmann surface area) method.

### Claim 8 (depends on 1)

The method of claim 1, wherein the binding free energies between ligands and TR used for predictions of thyroid disrupting potencies in step 5) are following the rules: for prediction of passive antagonistic potencies, binding free energies are calculated by use of MD trajectories of passive antagonist-TR complexes in step 1); for prediction of active antagonistic and agonistic potencies, binding free energies are calculated by use of MD trajectories of active antagonist-TR-corepressor and agonist-TR-coactivator complexes, respectively, in step 4).
